Krystal Biotech (KRYS)
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
$339.06
vs last close−11.82 (−3.37%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 102.13% | 30.23M shares | |
|---|---|---|---|
| 441 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.89% | 1.45M shares | |
| 5 holders · as of Sep 4, 2026 | |||
| Strategic holders | 5.42% | 1.61M shares | |
| 1 holder · as of Feb 3, 2022 | |||
| Adds to | 112.44% | ||
29.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.44%; nothing is left for Other.
13F, as of Jun 30, 2026
441 holders · 30.23M shares · 94 new positions · 273 increased · 112 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 4.42M | 14.93% | +44.2K | Aug 13, 2026 |
| BlackRock, Inc. | 4.18M | 14.13% | +241.0K | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 2.89M | 9.76% | 0 | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 1.57M | 5.32% | +118.2K | Aug 13, 2026 |
| State Street Corp | 1.35M | 4.56% | +36.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.24M | 4.19% | +75.2K | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 939.3K | 3.17% | −213.8K | Aug 11, 2026 |
| Capital World Investors | 777.8K | 2.63% | −46.9K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Krish S. Krishnanincl. Suma M. Krishnan | 11.50% | 3.39M | 13G | May 4, 2026 |
| State Street Corporation | 5.10% | 1.45M | Oct 16, 2024 | |
| Vanguard Portfolio Management | 5.05% | 1.48M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 4, 2026 | Krish S. Krishnandirector, 10 percent owner, officer: President and CEO | Sale · 13 lots | 25,000 | $359.32 | 1,347,543 |
| Sep 4, 2026 | Suma Krishnandirector, 10 percent owner, officer: President, R&D | Sale · 13 lots | 25,000 | $359.32 | 1,302,145 |
| Aug 14, 2026 | Dino A. Rossidirector | Sale · 8 lots | 25,000 | $329.12 | 50,000 |
| Jun 25, 2026 | John Charles Thomasofficer: EVP, General Counsel | Sale | 1,000 | $347.27 | 0 |
| Jun 4, 2026 | Krish S. Krishnandirector, 10 percent owner, officer: President and CEO | Sale · 11 lots | 25,000 | $308.12 | 1,450,253 |
| Jun 4, 2026 | Suma Krishnandirector, 10 percent owner, officer: President, R&D | Sale · 11 lots | 25,000 | $308.11 | 1,378,155 |
| May 26, 2026 | John Charles Thomasofficer: EVP, General Counsel | Sale | 642 | $302.03 | 0 |
| Mar 4, 2026 | Krish S. Krishnandirector, 10 percent owner, officer: President and CEO | Sale · 10 lots | 25,000 | $263.17 | 1,475,253 |
| Mar 4, 2026 | Suma Krishnandirector, 10 percent owner, officer: President, R&D | Sale · 10 lots | 25,000 | $263.21 | 1,403,155 |
| Feb 27, 2026 | Daniel Janneydirector | Sale · 2 lots | 11,803 | $275.59 | 73,293 |
House and Senate disclosures
Not reported.